ライフサイエンスコーパス: dyslipidemia

1 n hydrolysis, improved glucose tolerance and dyslipidemia.

2 ressure, insulin resistance, and atherogenic dyslipidemia.

3 veral metabolic traits including obesity and dyslipidemia.

4 glucose intolerance, insulin resistance, and dyslipidemia.

5 T1D, which aggravates both hyperglycemia and dyslipidemia.

6 view focused on screening for multifactorial dyslipidemia.

7 e investigated in hamsters with diet-induced dyslipidemia.

8 uch as insulin resistance, hypertension, and dyslipidemia.

9 recommend statins as first-line therapy for dyslipidemia.

10 2 diabetes, and diabetic patients often have dyslipidemia.

11 derappreciated cause of cirrhosis and severe dyslipidemia.

12 eutic target for metabolic disorders such as dyslipidemia.

13 independently of hypertension, diabetes, and dyslipidemia.

14 CRF levels may help delay the development of dyslipidemia.

15 eem to be safe and effective for adults with dyslipidemia.

16 in the treatment of diet-induced obesity and dyslipidemia.

17 and raises HDL (+73%) in a hamster model of dyslipidemia.

18 esence of type 2 diabetes, hypertension, and dyslipidemia.

19 een associated with the surge in obesity and dyslipidemia.

20 he development of cholestasis and associated dyslipidemia.

21 ide/low high-density lipoprotein cholesterol dyslipidemia.

22 nts who were not on baseline medications for dyslipidemia.

23 irubin, body mass index, hemoglobin A1C, and dyslipidemia.

24 re therapeutic strategy for the treatment of dyslipidemia.

25 and diabetes may be beneficial in improving dyslipidemia.

26 renal parenchymal hypertension and secondary dyslipidemia.

27 stment for age, sex, hypertension, race, and dyslipidemia.

28 inflammation pose a higher risk for CVD than dyslipidemia.

29 ased energy intake, increased adiposity, and dyslipidemia.

30 diet-induced obesity, insulin resistance and dyslipidemia.

31 lowering of LDL-C levels or non-LDL-related dyslipidemia.

32 esistance appeared earlier than the reducing dyslipidemia.

33 n type 9 (PCSK9) are an emerging therapy for dyslipidemia.

34 ng syndrome, which are associated with frank dyslipidemia.

35 cterized by insulin resistance, obesity, and dyslipidemia.

36 a discovery technique in suspected monogenic dyslipidemias.

37 to identify novel genes underlying monogenic dyslipidemias.

38 5 [0.44-0.67]), cardiometabolic comorbidity (dyslipidemia, 0.28 [0.22-0.37]), hypertension (0.59 [0.5

39 us (15.5%-5.9%), hypertension (29.7%-19.5%), dyslipidemia (14.0%-6.8%), and sleep apnea (9.6%-2.6%) w

40 (5 guidelines), dysglycemia (7 guidelines), dyslipidemia (2 guidelines), and hypertension (3 guideli

41 yopathy (4.0% v 2.6%), stroke (4.8% v 3.3%), dyslipidemia (33.9% v 22.3%), and diabetes (14.3% v 11.7

42 obese or overweight, 50.8% smoked, 56.5% had dyslipidemia, 39.9% had prehypertension, 10.0% had hyper

43 P<0.01), hypertension (68% vs 52%; P<0.05), dyslipidemia (48% vs 31%; P<0.05), and cardiovascular di

44 sensitivity C-reactive protein levels (75%), dyslipidemia (50%), elevated blood pressure (49%), impai

45 least in part through effects on atherogenic dyslipidemia, a cluster of traits including small, dense

46 lic abnormalities, which could contribute to dyslipidemia, a component of metabolic syndrome and diab

47 mellitus (DM2), and, as recently described, dyslipidemia, a condition with alterations in blood lipi

48 e comprehensively examined the prevalence of dyslipidemia, a major risk factor for cardiovascular dis

49 ithout obesity who do not have hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes

50 e cardiovascular risk factors (hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes

51 Dyslipidemia (adjusted relative risk = 1.60 [95% CI, 1.2

52 ower increases in lipid parameters and fewer dyslipidemia AEs than EFV-based treatment.

53 Dyslipidemia AEs were less common with RPV than with EFV

54 o determine how racial/ethnic differences in dyslipidemia affect racial/ethnic differences in cardiov

55 In total, 201 schizophrenia patients with dyslipidemia after being treated with an antipsychotic w

56 ention of type 2 diabetes, hypertension, and dyslipidemia after Roux-en-Y gastric bypass.

57 o-step enantioselective synthesis of an anti-dyslipidemia agent is demonstrated.

58 en Alzheimer disease (AD), inflammation, and dyslipidemia, although the nature of this relationship i

59 was to identify racial/ethnic differences in dyslipidemia among minorities including Asian Americans

60 gether, our findings suggest that Nef causes dyslipidemia and accumulation of cholesterol in macropha

61 Using breast cancer, dyslipidemia and Alzheimer's disease as case studies, we

62 l fatty acid oxidation, insulin sensitivity, dyslipidemia and aortic streaking in this mouse model.

63 Dyslipidemia and apolipoprotein E4 (APOE 4) allele are r

64 o discover novel and effective therapies for dyslipidemia and atherosclerosis, we have developed a se

65 of therapeutic utility in the prevention of dyslipidemia and atherosclerosis.

66 ases in central obesity, insulin resistance, dyslipidemia and blood pressure, as well as more extensi

67 therapeutic development for the treatment of dyslipidemia and cardiovascular disease.

68 Dyslipidemia and chronic inflammation may play a role in

69 nvincing evidence for an association between dyslipidemia and colorectal neoplasia was observed for h

70 fatty acids (TFAs) may increase the risk of dyslipidemia and coronary artery disease (CAD), limited

71 ll-established lifestyle factors influencing dyslipidemia and currently; 157 genetic susceptibility l

72 e intake was associated with greater risk of dyslipidemia and diabetes (ORs, 1.4 to 1.8; P </= .01),

73 A systematic review and meta-analysis of dyslipidemia and diabetic macular edema (DME).

74 amine the evidence of an association between dyslipidemia and DME.

75 HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models

76 olysis causes metabolic disorders, including dyslipidemia and hepatic steatosis.

77 In type 2 diabetes (T2DM), dyslipidemia and hyperglycemia damage DRG neurons and in

78 tes to the development of hepatic steatosis, dyslipidemia and hyperglycemia.

79 bile acids in the gut and are used to treat dyslipidemia and hyperphosphatemia.

80 agents and insulin), control (hyperglycemia, dyslipidemia and hypertension) and chronic microvascular

81 the lipid-lowering drug fenofibrate reverses dyslipidemia and improves insulin sensitivity in type 2

82 ssociated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contribu

83 effective in improving antipsychotic-induced dyslipidemia and insulin resistance, and the effects imp

84 temically, the metabolic syndrome, including dyslipidemia and insulin resistance, occurs in the setti

85 tein cholesterol (LDL-C), is associated with dyslipidemia and markers of atherosclerosis in young adu

86 olic risk factors including hypertension and dyslipidemia and may progress to liver fibrosis.

87 Dyslipidemia and myocardial infarction remain leading ca

88 Dyslipidemia and obesity are especially prevalent in pop

89 architecture leads to a higher incidence of dyslipidemia and obesity in modern Mexicans.

90 increased platelet reactivity are common in dyslipidemia and oxidative stress.

91 been supported as a susceptibility locus for dyslipidemia and related metabolic disorders in congenic

92 impairment; however, these mice also develop dyslipidemia and severe atherosclerosis.

93 enes demonstrate genetic connections between dyslipidemia and type 2 diabetes.

94 e metabolic consequences of obesity, such as dyslipidemia and type 2 diabetes.

95 pharmacological profile for the treatment of dyslipidemia and type 2 diabetes.

96 Analyses of linear trends in dyslipidemias and BP were conducted overall and separate

97 s to reveal new therapeutic targets to treat dyslipidemias and related cardiovascular disorders.

98 sk factors (diabetes mellitus, hypertension, dyslipidemia) and diseases (ischemic heart disease, cere

99 besity, smoking, diabetes, hypertension, and dyslipidemia), and the total number of late-life cardiac

100 baseline, 774 (33%) had diabetes, 1252 (63%) dyslipidemia, and 1601 (68%) hypertension.

101 of diabetes mellitus, 59% hypertension, 55% dyslipidemia, and 59% had a body mass index >/=30.

102 etabolic syndrome, as are central adiposity, dyslipidemia, and a predisposition to type 2 diabetes, a

103 reased tissue and systemic oxidative stress, dyslipidemia, and an enhanced proinflammatory status of

104 ma APOL1 levels with plasma cytokine levels, dyslipidemia, and APOL1 genotype in a nested case-contro

105 syndrome, particularly abdominal adiposity, dyslipidemia, and atherogenesis.

106 sociated with increased obesity progression, dyslipidemia, and atherosclerosis in hyperlipidemic Mir1

107 actor for post-transplantation hypertension, dyslipidemia, and diabetes (ORs >/= 2.0; P < .001).

108 Measures of insulin resistance, dyslipidemia, and diabetes mellitus also were associated

109 Among HCT survivors, hypertension, dyslipidemia, and diabetes were independent risk factors

110 isting cardiovascular factors (hypertension, dyslipidemia, and diabetes) and preexisting cardiovascul

111 filtration and inflammation in visceral pad, dyslipidemia, and ectopic fat accumulation.

112 have been associated with beta-cell strain, dyslipidemia, and endothelial dysfunction.

113 ncreased visceral adipose tissue, marked IR, dyslipidemia, and fatty liver.

114 ronic kidney disease, diabetes mellitus, and dyslipidemia, and had more often a non-LBBB (left bundle

115 vestigated the association between diabetes, dyslipidemia, and HCC mortality in those aged 40 years o

116 ategy to treat insulin resistance, diabetes, dyslipidemia, and hepatic steatosis.

117 iated with inflammation, insulin resistance, dyslipidemia, and high blood pressure, but their causal

118 Age, hypertension, diabetes, dyslipidemia, and hyperhomocysteinemia were established

119 was found that age, hypertension, diabetes, dyslipidemia, and hyperhomocysteinemia were found signif

120 have systemic effects on insulin resistance, dyslipidemia, and hypertension.

121 areas, including heart failure, arrhythmias, dyslipidemia, and hypertension.

122 tors: current smoking, overweight, diabetes, dyslipidemia, and hypertension.

123 onship between hypertension (HTN), diabetes, dyslipidemia, and incident severe AS requiring hospitali

124 abnormalities, including insulin resistance, dyslipidemia, and increased body mass index.

125 isk factors including obesity, diabetes, and dyslipidemia, and insulin resistance (IR) is the central

126 itrus flavonoids prevents hepatic steatosis, dyslipidemia, and insulin resistance primarily through i

127 ardiometabolic risk factors such as obesity, dyslipidemia, and insulin resistance.

128 x disorders including obesity, hypertension, dyslipidemia, and insulin resistance.

129 state and may result in visceral adiposity, dyslipidemia, and insulin resistance.

130 nd strongly associated with central obesity, dyslipidemia, and insulin resistance.

131 increased fructose consumption and obesity, dyslipidemia, and insulin resistance.

132 pNaKtide not only improved steatohepatitis, dyslipidemia, and insulin sensitivity, but also ameliora

133 ysiologic roles in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic steatohepatitis, and thei

134 mponents of diabetes mellitus, hypertension, dyslipidemia, and obesity.RESULTS When compared with the

135 dex >50 kg/m, type 2 diabetes, hypertension, dyslipidemia, and sleep apnea were found to be significa

136 risk associated with hypertension, diabetes, dyslipidemia, and smoking, these risk factors remain poo

137 flow from WAT led to marked hepatosteatosis, dyslipidemia, and systemic insulin resistance in high-fa

138 Obesity and dyslipidemia are hallmarks of metabolic and cardiovascul

139 t accumulation, as reflected by the FLI, and dyslipidemia, as reflected by triglycerides, may partly

140 Dyslipidemia associated with triglyceride-rich lipoprote

141 We assessed whether 234 established dyslipidemia-associated loci modify the effects of metfo

142 with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries.

143 ve comorbid hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, anemia, and renal dys

144 gher frequency of cardiovascular disease and dyslipidemia both before and after LT.

145 retion, have potential to effectively reduce dyslipidemia but can also lead to hepatic accumulation o

146 Amorfrutins improve insulin sensitivity and dyslipidemia but do not enhance undesired fat storage.

147 Obesity is a major risk factor for dyslipidemia, but this relationship is highly variable.

148 Prevention and sensible management of dyslipidemia can markedly alter cardiovascular morbidity

149 uding insulin resistance, hyperglycemia, and dyslipidemia, can further impact tumor growth and develo

150 ch as type 2 diabetes, cancer, hypertension, dyslipidemia, cardiovascular disease, and sleep apnea.

151 tifactorial disease cluster that consists of dyslipidemia, cardiovascular disease, type 2 diabetes me

152 IDOL-induced dyslipidemia caused formation of atherosclerotic lesions

153 g of cardiometabolic risk factors, including dyslipidemia, central adiposity, hypertension, and hyper

154 Multifactorial dyslipidemia, characterized by elevated total cholestero

155 hted combination of modifiable risk factors: dyslipidemia, cigarette smoking, hypertension, obesity,

156 osclerotic cardiovascular disease or genetic dyslipidemia; clarifying a diagnosis of metabolic syndro

157 iglycerides improved the prediction of adult dyslipidemia compared with clinical childhood risk facto

158 es improved the accuracy of predicting adult dyslipidemia compared with the approach using only child

159 g the central abnormality of the atherogenic dyslipidemia complex, the elevation of triglyceride-rich

160 n correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD events.

161 resulted in an epidemic of the "atherogenic dyslipidemia complex," the main features of which includ

162 nown to modify components of the atherogenic dyslipidemia complex.

163 apeutic strategies to modify the atherogenic dyslipidemia complex.

164 Hyperglycemia and dyslipidemia contribute to glucolipotoxicity that leads

165 ex, mitral regurgitation, diabetes mellitus, dyslipidemia, coronary artery disease severity, implanta

166 fter multivariable adjustment, hypertension, dyslipidemia, coronary artery disease, prior myocardial

167 om 0.665 when considering only risk factors (dyslipidemia, current smoking, hypertension, diabetes, a

168 ively reduced CVD in study participants with dyslipidemia, defined as triglyceride levels greater tha

169 n of type 2 diabetes mellitus, hypertension, dyslipidemia, depression, and sleep apnea, and changes i

170 c peripheral arterial disease (PAD), such as dyslipidemia, diabetes mellitus, and hypertension, are h

171 ociated with CVD risk factors (hypertension, dyslipidemia, diabetes mellitus, obesity, smoking, heavy

172 of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a

173 ese among adults without known hypertension, dyslipidemia, diabetes, or impaired fasting glucose.

174 erapy; HIV-associated comorbidities, such as dyslipidemia, drug abuse, and opportunistic infections;

175 ic hypertension, diabetes mellitus, obesity, dyslipidemia, drug dependence or tobacco use, and renal

176 tional risk factors such as hypertension and dyslipidemia due to secondary renal parenchymal hyperten

177 ender, baseline diabetes, SBP, BMI, smoking, dyslipidemia, eGFR, folate and vitamin B12 levels.

178 ein levels, impaired fasting glucose levels, dyslipidemia, elevated blood pressure, and diabetes mell

179 Worldwide clinical practice guidelines for dyslipidemia emphasize allocating statin therapy to thos

180 tors (CVRFs; ie, diabetes, hypertension, and dyslipidemia), ethnicity, smoking, and overweight/obesit

181 Across the spectrum of dyslipidemia, event rates similar to secondary preventio

182 with primary hypercholesterolemia and mixed dyslipidemia, evolocumab added to moderate- or high-inte

183 ty; no history of hypertension, diabetes, or dyslipidemia; family history of premature coronary arter

184 tose appears to be more lipogenic, promoting dyslipidemia, fatty liver disease, cardiovascular diseas

185 e associated with an increased risk of adult dyslipidemia for all lipids.

186 cal practice guideline for the management of dyslipidemia for cardiovascular disease risk reduction i

187 Dyslipidemia has been associated with an increased risk

188 ent of vision in patients with diabetes, and dyslipidemia has been reported as a risk factor for its

189 Screening of children for multifactorial dyslipidemia has not been evaluated in randomized clinic

190 HTN, diabetes, and dyslipidemia have independent and dose-response associat

191 Hypertension and dyslipidemia have traditionally been associated with die

192 and accelerated thrombosis, specifically in dyslipidemia, have been mechanistically linked to the ac

193 Carriers of the mutation had dyslipidemia, hepatic steatosis, systemic insulin resist

194 nd sex hormone-binding globulin), markers of dyslipidemia (high-density lipoprotein cholesterol and t

195 he algorithm-based fatty liver index (FLI)], dyslipidemia (high-density lipoprotein cholesterol, trig

196 etes mellitus (HR, 2.84; 95% CI, 1.92-4.19), dyslipidemia (HR, 1.48; 95% CI, 1.01-2.15), and 3 or mor

197 abetes (HR: 1.49; 95% CI: 1.44 to 1.54), and dyslipidemia (HR: 1.17; 95% CI: 1.14 to 1.21) were all s

198 HF diet caused excess weight gain, dyslipidemia, hyperinsulinemia, and mild glucose intoler

199 discussed concerning body fat distribution, dyslipidemia, hypertension, diabetes mellitus, inflammat

200 various cardiovascular risk factors such as dyslipidemia, hypertension, diabetes, and altered metabo

201 cardiovascular disease risk factors, such as dyslipidemia, hypertension, metabolic syndrome, and diab

202 bolic abnormalities, including hypertension, dyslipidemia, impaired carbohydrate metabolism, and nona

203 d have known CVD risk factors (hypertension, dyslipidemia, impaired fasting glucose, or the metabolic

204 Dyslipidemia impairs mitochondrial trafficking and funct

205 ension was diagnosed in 29 patients (13.2%), dyslipidemia in 55 patients (25.1%), impaired fasting gl

206 in 74% (95% CI, 64 to 84), and remission of dyslipidemia in 66% (95% CI, 57 to 74).

207 sma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.

208 e identification of those at highest risk of dyslipidemia in adulthood.

209 and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits

210 n screening for or treatment of asymptomatic dyslipidemia in adults aged 21 to 39 years.

211 ntary adults with abdominal obesity (75%) or dyslipidemia in an isolated workplace with a monitored p

212 Screening for dyslipidemia in childhood could delay or reduce cardiova

213 11 newly recommended universal screening for dyslipidemia in children at 9 to 11 years and 17 to 21 y

214 ipid levels enhances the prediction of adult dyslipidemia in comparison to childhood lipid measures.

215 mia is associated with maternal prepregnancy dyslipidemia in excess of measured lifestyle, anthropome

216 degree of adiposity, insulin resistance, and dyslipidemia in KW mice was not influenced by Nox1 delet

217 pose tissue and skeletal muscle and improves dyslipidemia in mice and humans.

218 fat mass development, insulin resistance and dyslipidemia in mice.

219 and to identify the role of hypertension and dyslipidemia in the development of the reported alterati

220 ating the potential effects of screening for dyslipidemia in this population requires extrapolation f

221 Salsalate improves glucose intolerance and dyslipidemia in type 2 diabetes patients, but the mechan

222 contributor to early insulin resistance and dyslipidemia in uremia.

223 Dyslipidemia in young adults in the United States during

224 public health efforts to identify and reduce dyslipidemia in young adults prior to their childbearing

225 s and harms of screening for or treatment of dyslipidemia in younger adults remains unavailable.

226 e underlying pathophysiology of this form of dyslipidemia, in particular its association with insulin

227 ses including obesity and metabolic disease, dyslipidemia, inflammation, atherosclerosis, hypertensio

228 d treatment of other risk factors, including dyslipidemia, insulin resistance and diabetes mellitus,

229 le for citrus flavonoids in the treatment of dyslipidemia, insulin resistance, hepatic steatosis, obe

230 ompasses a cluster of risk factors including dyslipidemia, insulin resistance, increased blood pressu

231 Dyslipidemia is a major modifiable risk factor for cardi

232 Dyslipidemia is a risk factor for premature cardiovascul

233 Dyslipidemia is an important risk factor for coronary ar

234 Dyslipidemia is associated with greater risk of ventricu

235 Adult offspring dyslipidemia is associated with maternal prepregnancy dy

236 It is unclear whether dyslipidemia is associated with risk of colorectal neopl

237 Dyslipidemia is one of the most common adverse effects i

238 However, when NA is used to treat dyslipidemias, it causes a strong side effect of cutaneo

239 ed LH/FSHD was associated with hypertension, dyslipidemia, low BMD, and slow walking; and both defici

240 Treatment of dyslipidemia may be an effective strategy to reduce cogn

241 Background: Dyslipidemia may occur in younger adults (defined as per

242 ren aged 8 to 10 years with mild to moderate dyslipidemia; mean between-group difference in TC change

243 The prevalence of dyslipidemia modestly decreased between 1999-2000 and 20

244 that KLF14 is dysregulated in the liver of 2 dyslipidemia mouse models.

245 r from lipid-related comorbidities including dyslipidemia, obesity, and fatty liver disease.

246 m have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans.

247 o determine the contribution of PCSK9 to the dyslipidemia of nephrotic syndrome.

248 Individuals with dyslipidemia often develop type 2 diabetes, and diabetic

249 The effects of dyslipidemia on the risk of type 2 diabetes (T2D) and re

250 risk factors (CVRFs; hypertension, diabetes, dyslipidemia) on long-term CVD risk in cancer survivors.

251 ved at week 24, but the effects on improving dyslipidemia only significantly occurred at the end of w

252 ssociated cardiometabolic risk factors (e.g.,dyslipidemia or hyperglycemia).

253 at least 27 if they had treated or untreated dyslipidemia or hypertension.

254 and three loci previously unassociated with dyslipidemia or obesity.

255 (OR: 0.25, 95% CI: 0.12-0.50, P < 0.001) and dyslipidemia (OR: 0.21, 95% CI: 0.10-0.44, P < 0.001) we

256 itional metabolic risk factor (hypertension, dyslipidemia, or diabetes) (aOR, 6.54 [95% CI, 1.87-22.8

257 ncident retinal vascular pathology, obesity, dyslipidemia, or hyperglycemia.

258 ving a series of pathological events such as dyslipidemia, oxidative stress, and blood clotting mecha

259 in a late model of atherosclerosis in which dyslipidemia plays the main pathogenic role.

260 Eatment with PItavastatin vs pravastatin for Dyslipidemia) randomised, double-blind, active-controlle

261 Data were collected from the Spanish Dyslipidemia Registry of the Spanish Atherosclerosis Soc

262 h is needed to elucidate why having baseline dyslipidemia relates to lower future HCC mortality.

263 Dyslipidemia remission rates were 93.3% (28/30) for tota

264 .S. Preventive Services Task Force review on dyslipidemia screening in younger adults.

265 ylomicron production rate contributes to the dyslipidemia seen in common metabolic disorders such as

266 With regard to dyslipidemia, significant results were found for decreas

267 tion of Mecp2 causes fatty liver disease and dyslipidemia similar to HDAC3 liver-specific deletion.

268 Common vascular risk factors (dyslipidemia, smoking, and sex) were similar for normal,

269 ss index, history of hypertension, diabetes, dyslipidemia, smoking, angina, beta-blocker use, prior r

270 The PSR group also had more diabetes, dyslipidemia, smoking, infarcts from small-vessel diseas

271 dized prevalence rates were calculated for 3 dyslipidemia subtypes: high triglycerides (fasting labor

272 Outcomes included dyslipidemia (TC>/=200 mg/dL or LDL-C>/=130 mg/dL) and a

273 nd lower incidence rates of hypertension and dyslipidemia than did nonsurgery group 1 (P<0.05 for all

274 to have hypertension, diabetes mellitus, and dyslipidemia than normal or underweight patients.

275 ept for gastro-esophageal reflux disease and dyslipidemia that appear to be more successfully treated

276 has led to the development of therapies for dyslipidemia that inhibit MTP.

277 Only p.G116S was associated with dyslipidemia: the increase in LDL cholesterol was 0.54 m

278 rmacotherapy with mTOR inhibitors aggravates dyslipidemia, thus necessitating lipid-lowering therapy

279 drome patients also show signs of peripheral dyslipidemia; thus, together these data suggest that RTT

280 tory of hypertension, diabetes mellitus, and dyslipidemia; tobacco and alcohol use; and APOE epsilon4

281 The dyslipidemia trial compared fenofibrate plus simvastatin

282 s in the primary outcome in the glycemia and dyslipidemia trials, but no significant effect in the bl

283 in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthri

284 graphics and the APOE genotype, only midlife dyslipidemia was associated with amyloid deposition.

285 Dyslipidemia was present in 78% of subjects, hypertensio

286 rmonal dysregulation, hepatic steatosis, and dyslipidemia was reduced or reversed in mice lacking the

287 lop novel treatments for type 2 diabetes and dyslipidemia, we pursued inhibitors of serine palmitoyl

288 opment of atherosclerosis, inflammation, and dyslipidemia were assessed.

289 existing diabetes mellitus, hypertension, or dyslipidemia were at significantly greater risk (P<0.001

290 Age, sex, smoking, and dyslipidemia were more strongly associated with femoral

291 tabolic alterations relevant to postprandial dyslipidemia were previously identified in the intestine

292 <3 years, worse baseline visual acuity, and dyslipidemia were significant risk factors for failure.

293 es mellitus (DM), body mass index (BMI), and dyslipidemia were used.

294 n with maternal postpartum weight status and dyslipidemia, whereas more evidence exists for an associ

295 ept for gastro-esophageal reflux disease and dyslipidemia, which were more successfully treated by LR

296 for treatment of the metabolic syndrome and dyslipidemia, while avoiding systemic toxicity.

297 ht identify younger adults with asymptomatic dyslipidemia who may benefit from lipid-lowering therapi

298 Type 2 diabetes is often accompanied by dyslipidemia with elevated levels of free fatty acids (F

299 Both groups improved dyslipidemia, with reduced circulating triglycerides, bu

300 IDOL-induced dyslipidemia worsened albuminuria and glomerular macroph